Anne-Laure Louveau

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer

Guy Jérusalem, Richard H. De Boer, Sara A. Hurvitz et al. · JAMA Oncology · 2018 · 110 citations · Full text

Medicine, Oncology, Pharmacology +17

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis

John J. Bissler, Norio Nonomura, Klemens Budde et al. · PLoS ONE · 2018 · 32 citations · Full text

Medicine, Oncology, Radiology +17

PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

Thomas E. Witzig, Kensei Tobinai, Luigi Rigacci et al. · Journal of Clinical Oncology · 2016 · 18 citations

Pharmacy, Oncology, Pharmacotherapy +17

Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results.

Alain Ravaud, Carlos H. Barrios, B. Yа. Alekseev et al. · Journal of Clinical Oncology · 2013 · 12 citations

Medicine, Oncology, Pharmacotherapy +16